Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: temporary discontinuation of hormone therapy for 1 month, temporary discontinuation of hormone therapy for 2 months; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 1,704 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
Interventions: Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer; Drug · Combination Product
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm
Interventions: Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate; Other · Procedure · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Systemic Lupus Erythematosus
Interventions: estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older · Female only
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Breast Cancer
Interventions: Avelumab, Endocrine therapy, Palbociclib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more

Conditions: Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Interventions: Nutritional Intervention, Physical Activity Intervention; Combination Product · Behavioral
Lead sponsor: Siobhan Trotter; Other
Eligibility: 25 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Fabry Disease
Interventions: DRX005B; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
Interventions: Prismocitrate 18, PrisMax System Version 3.x with calcium line accessory; Drug · Device
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 10 more

Conditions: Fabry Disease, Proteinuria
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 95 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Acute Kidney Injury, Fluid Overload
Interventions: Continuous Renal Replacement Therapy; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year to 25 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COVID-19
Interventions: Arginine Hydrochloride; Drug
Lead sponsor: Emory University; Other
Eligibility: 3 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cigarette Smoking
Interventions: Best Practices, Financial Incentives, Nicotine Replacement Therapy; Behavioral · Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older · Female only
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Smoking, Homeless Persons
Interventions: Bupropion, Nicotine replacement therapy, Contingency Management; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Endothelial Dysfunction
Interventions: Nicotine Replacement Therapy (NRT), Gamma-Tocopherol, Placebo, Smoking cessation; Other · Dietary Supplement · Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 60 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Nicotine Dependence
Interventions: nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol), denicotinized cigarettes (Quest 3 cigarettes); Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Smoking Cessation
Interventions: High intensity disease management, Low intensity disease management, Comparison group, Bupropion; Behavioral · Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Smoking ( Cigarette)
Interventions: Nicotine replacement therapy patches, Oral nicotine pouches; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone; Procedure · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Tobacco Use Disorder, Tobacco Dependence
Interventions: Quitbuddy, Control, SDoH Augmentation, SDoH Control; Other
Lead sponsor: Bryan W. Heckman; Other
Eligibility: 21 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hunter Syndrome
Interventions: idursulfase-IT, No IT treatment; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: Up to 18 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina

Conditions: Smoking Cessation
Interventions: Self-help materials, nicotine patch, Counseling, Smartphone-delivered automated treatment; Behavioral · Drug · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: E Cigarette Use, Cessation, Tobacco, Cessation, Nicotine
Interventions: Nicotine Replacement Therapies, Brief Behavioral Counseling; Drug · Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Greenville, North Carolina • Morgantown, West Virginia

Conditions: Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions: MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study); Genetic · Procedure
Lead sponsor: Celladon Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 22
States / cities: San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more

Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions: Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution; Other
Lead sponsor: University of Calgary; Other
Eligibility: 9 Months to 21 Years
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more

Search by objective public record fields.

Radiologic Evaluation and Breast Density (READ)

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery

Alpha-Galactosidase A Replacement Therapy for Fabry Disease

Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

Antiproteinuric Agents and Fabry Disease

Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI

Arginine Replacement Therapy in COVID-19

Financial Incentives for Smoking Cessation Among Mothers

Contingency Management for Smoking Cessation in Homeless Smokers

Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function

Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes

Disease Management for Smoking Cessation

Piloting Novel Interventional Strategies to Improve Nicotine Pouches as a Substitute for Smoking

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Equitable Smoking Relapse Prevention

Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

Smartphone-delivered Automated Video-assisted Smoking Treatment for People Living With HIV

Evaluation of Dependence and Nicotine Replacement Therapy-Supported Cessation Efforts Among Regular Electronic Cigarette Use

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection